Completed NA INTERVENTIONAL 1-arm NCT00943839

Sunitinib Malate in Treating Patients With Kidney Cancer

Effects of Sunitinib in the Expression of VEGF and of Interleukin 6 and CXCL7 - CXCL5 Cytokins : Explanation of Anti-angiogenic Effects.

Sponsor: Centre Antoine Lacassagne

Conditions Kidney Cancer

Interventions laboratory biomarker analysis pharmacological study sunitinib malate

Updated 5 times since 2017 Last updated: Nov 9, 2016 Started: Feb 28, 2009 Primary completion: Nov 30, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Kidney Cancer and is currently completed. Centre Antoine Lacassagne leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Antoine Lacassagne

Data source: Centre Antoine Lacassagne

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nice, France